NEW YORK, Sept. 21, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Altimmune, Inc. (NASDAQ: ALT) between August 10, 2023 and June 25, 2025 (the “Class Period”), of the important October 6, 2025 lead plaintiff deadline. SO WHAT: If you purchased Altimmune securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT TO DO NEXT: To join the Altimmune class acti ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Altimmune To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $75,000 in Altimmune between August 10, 2023 and June 25, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, Sept. 21, 2025 (GLOB ...

诉讼背景 - 罗森律师事务所提醒在2023年8月10日至2025年6月25日期间购买Altimmune公司（NASDAQ: ALT）证券的投资者注意2025年10月6日的重要首席原告截止日期 [1] - 投资者可能无需支付任何自付费用或成本即可通过应急费用安排获得补偿 [1] 诉讼程序 - 投资者可通过指定网址提交表格或联系Phillip Kim律师加入集体诉讼 [2][5] - 首席原告需在2025年10月6日前向法院提出申请 代表其他集体成员指导诉讼 [2] - 在集体认证前 投资者需自行保留律师或选择作为缺席集体成员不采取行动 [6] 律所资质 - 罗森律师事务所专注于证券集体诉讼和股东派生诉讼 2017年因证券集体诉讼和解数量被ISS评为第一 [3] - 2013年以来每年排名前四 2019年单独为投资者追回超过4.38亿美元 [3] - 2020年创始合伙人Laurence Rosen被law360评为原告律师界泰斗 [3] 案件细节 - 指控被告在集体诉讼期间制造关于Altimmune公司IMPACT Phase 2b MASH试验结果的虚假信息 [4] - Altimmune未能达到纤维化减少主要终点的统计学显著性标记 但持续吹捧对顶线结果的过高预期 [4] - 公司隐瞒安慰剂组更高反应率 该情况对顶线结果产生负面影响 真实细节披露后投资者遭受损失 [4]

Accessibility StatementSkip Navigation NEW YORK, Sept. 15, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Altimmune, Inc. (NASDAQ: ALT). Shareholders who purchased shares of ALT during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. SOURCE The Gross Law Firm WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? CONTACT US HERE: https://s ...

GAITHERSBURG, Md., Sept. 15, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced the appointment of Linda M. Richardson to the role of Chief Commercial Officer, effective September 16, 2025. Ms. Richardson joins the Company with more than 30 years of experience in sales and marketing, commercial, corporate and business development across a range of therapeut ...

Altimmune集体诉讼事件 - 公司因Pemvidutide治疗MASH的IMPACT Phase 2b试验未达到主要终点统计显著性而面临集体诉讼 试验显示纤维化改善呈积极趋势但未能实现统计显著性 原因为安慰剂反应高于预期 [2] - 公司高管在结果公布后回应冷淡 将失败归因于二期试验性质 并称期待三期试验获得更好结果 [2] - 股价在2025年6月26日单日暴跌53.2% 从6月25日收盘价7.71美元/股跌至3.61美元/股 [3] SelectQuote集体诉讼事件 - 美国司法部于2025年5月1日提起《虚假申报法》诉讼 指控公司在2016至2021年间通过收取保险公司数千万美元非法回扣操纵医疗保险计划推荐 [3] - 公司被指控与主要保险公司合谋歧视被视为利润较低的参保人（包括残障人士）并虚假宣传提供无偏见保险比较 [3] - 股价在诉讼日下跌19.2% 跌0.61美元至2.56美元/股 交易量异常放大 [3] - 诉讼指控公司在整个集体诉讼期隐瞒关键事实 包括未披露按回扣水平推荐保险计划、违反法律法规及面临法律制裁风险等 [4] 诉讼程序信息 - Altimmune集体诉讼期覆盖2023年8月10日至2025年6月25日 首席原告截止日期为2025年10月6日 [2] - SelectQuote集体诉讼期覆盖2020年9月9日至2025年5月1日 首席原告截止日期为2025年10月10日 [3]

SAN DIEGO, Sept. 12, 2025 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, PLLP, announces that a class action lawsuit has been filed on behalf of investors who purchased securities of Altimmune, Inc. (“Altimmune”) (NASDAQ: ALT) between August 10, 2023 and June 25, 2025, inclusive (the “Class Period”). If you wish to serve as lead plaintiff, you must move the Court no later than October 6, 2025. If you have incurred significant losses and want to act as the lead plaintiff in the class action ...

Accessibility StatementSkip Navigation NEW YORK, Sept. 12, 2025 /PRNewswire/ --Â Levi &Â Korsinsky, LLP notifies investors in Altimmune, Inc. ("Altimmune" or the "Company") (NASDAQ: ALT) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Altimmune investors who were adversely affected by alleged securities fraud between August 10, 2023 and June 25, 2025. Follow the link below to get more information and be contacted by a member of our team: CONTACT:Levi ...

NEW YORK, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Altimmune, Inc. ("Altimmune" or the "Company") (NASDAQ: ALT) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Altimmune investors who were adversely affected by alleged securities fraud between August 10, 2023 and June 25, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/altimmune-inc-lawsuit-subm ...

Question-and-Answer SessionWith that, we begin the Altimmune fireside chat, and we are excited to have you here. So for those who do not know the story of Altimmune, can you give us a brief background of yourselves and a brief background of the company at a higher level and what you're currently focused on?Vipin GargPresident, CEO & Director Absolutely. Well, thank you for having us. We appreciate it. I'm Vipin Garg, President and CEO of Altimmune; and my colleague, Dr. Scott Harris, our Chief Medical Offic ...